Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Capecitabine in Advanced Solid Tumors and Pancreatico-Biliary Cancers
NCT02451553Phase 1Completed
- Sponsor
- University of Washington
- Start
- Nov 2015
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afatinib in solid tumor, pancreatic cancer (PC) and biliary tract cancer (BTC), sponsored by University of Washington. Primary endpoints: Incidence of adverse events, Incidence of dose limiting toxicity up to 21 days and 2 more. Started Nov 2015; status: completed.
02
Drugs
afatinib
03
Conditions
solid tumorpancreatic cancer (PC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02451553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451553.